Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1229236-86-5
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C24H23N7O2
|
| gptkbp:hasSMILES |
C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2C(=O)NC4=CC=CC=C4C(=O)N5C=NC=NC5N
|
| https://www.w3.org/2000/01/rdf-schema#label |
gandotinib
|
| gptkbp:investigatedBy |
gptkb:polycythemia_vera
essential thrombocythemia primary myelofibrosis myeloproliferative neoplasms |
| gptkbp:molecularWeight |
441.49 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
46209416 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
LY2784544
|
| gptkbp:target |
gptkb:JAK2
|
| gptkbp:bfsParent |
gptkb:Janus_kinases
|
| gptkbp:bfsLayer |
8
|